However, using only serum AST, ALT, or the AST/ALT ratio as markers for severe MASLD demonstrates low sensitivity for hepatic fibrosis, potentially leading to the misclassification of high-risk patients as mild cases (15, 16). This evidence concerns the gene GPT and Hepatic fibrosis.